FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to using the compounds based on tetrapeptide and tripeptide groups and related peptoid groups in treating or preventing a cancer disease in an individual, which is characterised by a high-level expression or activity of Gadd45β as compared to common civilised cells if cancer cell viability and/or growth are/is stated dependent on NF-κB.
EFFECT: higher effectiveness of the method.
14 cl, 54 dwg, 9 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-T CELLS | 2020 |
|
RU2762942C1 |
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-NK-CELLS | 2020 |
|
RU2795443C2 |
| COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
| ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER DISEASES | 2019 |
|
RU2799547C2 |
| METHOD AND COMPOSITION FOR TREATING CANCER, DESTROYING METASTATIC CANCER CELLS AND PREVENTING METASTASES OF CANCER, USING ANTIBODIES TO END PRODUCTS OF INCREASED GLYCATION (AGE) | 2017 |
|
RU2728964C2 |
| AGENTS FOR THE TREATMENT OF CLAUDINE-EXPRESSING CANCER DISEASES | 2013 |
|
RU2798990C2 |
| HUMANIZED ANTIBODIES AGAINST CD269 (BCMA) | 2015 |
|
RU2749041C2 |
| ANTI-FcRH5 ANTIBODIES | 2014 |
|
RU2687132C2 |
| AMHRII BINDING COMPOUNDS FOR PREVENTING OR TREATING CANCER | 2018 |
|
RU2816523C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED B-CELL MATURATION ANTIGEN | 2013 |
|
RU2766608C2 |
